(The annual conference was held May 7-10 in Milan, Italy.) | ||||
Company (Location) |
Product |
Description |
Indication |
Status (Date)# |
Durata Therapeutics Inc. (Morristown, N.J.) |
Dalbavancin |
A long-acting, intravenous lipoglycopeptide antibiotic |
Acute bacterial infections of the skin |
Phase III data showed it was similar to linezolid in resolution of fever and cessation of lesion spread in acute bacterial infections of the skin (5/10) |
Inhibitex Inc. (Atlanta) and Pfizer Inc. (New York) |
SA3Ag |
A three-antigen vaccine |
Staphylococcus aureus |
Phase I data showed it elicited a positive immune response to each of the three components (5/10) |
Optimer Pharmaceuticals Inc. (San Diego) |
Dificid |
Fidaxomicin |
Clostridium difficile infection |
Phase III data showed that immunosuppression is associated with higher death and lower CDI cure rates and that the rate of CDI recurrence remained substantially lower among immunosuppressed patients treated with Dificid vs. vancomycin (5/11) |
PolyMedix Inc. (Radnor, Pa.) |
PMX-30063 |
Defensin-mimetic antibiotic |
Acute bacterial skin and skin structure infections caused by staph bacteria |
Clinical data reaffirmed that it does not cause nerve damage at the tested doses and indicated that interactions with ion channels are the underlying mechanism of the parasthesia (5/13) |
Tetraphase Pharmaceuticals Inc. (Watertown, Mass.) |
TP-434 |
Broad-spectrum antibiotic |
Multidrug-resistant Gram-negative pathogens |
Clinical data showed it is active and is largely unaffected by media age and media additives (5/10) |
Notes: Public biotech company stock symbols can be found in the stock report located on the last two pages of this issue. # The date indicated refers to the BioWorld Today issue in which the news item can be found. |